| An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells D Rohle, J Popovici-Muller, N Palaskas, S Turcan, C Grommes, ... Science 340 (6132), 626-630, 2013 | 1276 | 2013 |
| Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress J Tsoi, L Robert, K Paraiso, C Galvan, KM Sheu, J Lay, DJL Wong, M Atefi, ... Cancer cell 33 (5), 890-904. e5, 2018 | 672 | 2018 |
| Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ... Nature communications 5 (1), 5712, 2014 | 645 | 2014 |
| Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma S Hu-Lieskovan, S Mok, B Homet Moreno, J Tsoi, L Robert, L Goedert, ... Science translational medicine 7 (279), 279ra41-279ra41, 2015 | 593 | 2015 |
| Genetic mechanisms of immune evasion in colorectal cancer CS Grasso, M Giannakis, DK Wells, T Hamada, XJ Mu, M Quist, JA Nowak, ... Cancer discovery 8 (6), 730-749, 2018 | 424 | 2018 |
| CTLA4 blockade broadens the peripheral T-cell receptor repertoire L Robert, J Tsoi, X Wang, R Emerson, B Homet, T Chodon, S Mok, ... Clinical Cancer Research 20 (9), 2424-2432, 2014 | 398 | 2014 |
| Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma A Ribas, D Lawrence, V Atkinson, S Agarwal, WH Miller Jr, MS Carlino, ... Nature medicine 25 (6), 936-940, 2019 | 307 | 2019 |
| Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma CS Grasso, J Tsoi, M Onyshchenko, G Abril-Rodriguez, ... Cancer cell 38 (4), 500-515. e3, 2020 | 275 | 2020 |
| Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance Y Su, W Wei, L Robert, M Xue, J Tsoi, A Garcia-Diaz, B Homet Moreno, ... Proceedings of the National Academy of Sciences 114 (52), 13679-13684, 2017 | 222 | 2017 |
| Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells B Homet Moreno, JM Zaretsky, A Garcia-Diaz, J Tsoi, G Parisi, L Robert, ... Cancer immunology research 4 (10), 845-857, 2016 | 155 | 2016 |
| Immunotherapy resistance by inflammation-induced dedifferentiation A Mehta, YJ Kim, L Robert, J Tsoi, B Comin-Anduix, B Berent-Maoz, ... Cancer discovery 8 (8), 935-943, 2018 | 151 | 2018 |
| Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma DJL Wong, L Robert, MS Atefi, A Lassen, G Avarappatt, M Cerniglia, ... Molecular cancer 13, 1-15, 2014 | 126 | 2014 |
| Overcoming genetically based resistance mechanisms to PD-1 blockade DY Torrejon, G Abril-Rodriguez, AS Champhekar, J Tsoi, KM Campbell, ... Cancer Discovery 10 (8), 1140-1157, 2020 | 111 | 2020 |
| PAK4 inhibition improves PD-1 blockade immunotherapy G Abril-Rodriguez, DY Torrejon, W Liu, JM Zaretsky, TS Nowicki, J Tsoi, ... Nature Cancer 1 (1), 46-58, 2020 | 108 | 2020 |
| Precise T cell recognition programs designed by transcriptionally linking multiple receptors JZ Williams, GM Allen, D Shah, IS Sterin, KH Kim, VP Garcia, GE Shavey, ... Science 370 (6520), 1099-1104, 2020 | 105 | 2020 |
| A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab TS Nowicki, B Berent-Maoz, G Cheung-Lau, RR Huang, X Wang, J Tsoi, ... Clinical Cancer Research 25 (7), 2096-2108, 2019 | 84 | 2019 |
| Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist G Parisi, JD Saco, FB Salazar, J Tsoi, P Krystofinski, C Puig-Saus, ... Nature communications 11 (1), 660, 2020 | 82 | 2020 |
| Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition S Mok, J Tsoi, RC Koya, S Hu-Lieskovan, BL West, G Bollag, TG Graeber, ... BMC cancer 15, 1-10, 2015 | 57 | 2015 |
| Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti–PD-1 therapy YJ Kim, KM Sheu, J Tsoi, G Abril-Rodriguez, E Medina, CS Grasso, ... The Journal of clinical investigation 131 (12), 2021 | 42 | 2021 |
| CRAF R391W is a melanoma driver oncogene M Atefi, B Titz, J Tsoi, E Avramis, A Le, C Ng, A Lomova, A Lassen, ... Scientific reports 6 (1), 27454, 2016 | 19 | 2016 |
